About the Authors

Aurélien Lambert

Contributed equally to this work with: Aurélien Lambert, Marta Jarlier, Sophie Gourgou Bourgade, Thierry Conroy

Roles Formal analysis, Project administration, Validation, Writing – original draft, Writing – review & editing

a.lambert@nancy.unicancer.fr

Affiliation Department of medical oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France

Marta Jarlier

Contributed equally to this work with: Aurélien Lambert, Marta Jarlier, Sophie Gourgou Bourgade, Thierry Conroy

Roles Data curation, Formal analysis, Methodology, Writing – review & editing

Affiliation Biostatistics unit, Institut régional du cancer de Montpellier, Parc Euromédecine, Montpellier, France

Sophie Gourgou Bourgade

Contributed equally to this work with: Aurélien Lambert, Marta Jarlier, Sophie Gourgou Bourgade, Thierry Conroy

Roles Data curation, Formal analysis, Methodology, Writing – review & editing

Affiliation Biostatistics unit, Institut régional du cancer de Montpellier, Parc Euromédecine, Montpellier, France

Thierry Conroy

Contributed equally to this work with: Aurélien Lambert, Marta Jarlier, Sophie Gourgou Bourgade, Thierry Conroy

Roles Conceptualization, Investigation, Methodology, Project administration, Supervision, Validation, Writing – review & editing

Affiliation Department of medical oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France

Competing Interests

Oxaliplatin and irinotecan were donated by Sanofi-Aventis and Pfizer, respectively; these drug manufacturers had no role in the design of the study, in the accrual or analysis of the data, or in the preparation of the manuscript.